Anti-tpbg antibodies and methods of use

Abstract

The invention provides anti-TPBG antibodies and methods of using the same.

1 - 17 . (canceled) 
     
     
         18 . An isolated antibody that binds to trophoblast glycoprotein (TPBG) comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 11, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 12, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 13, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 14, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 15, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 16. 
     
     
         19 . The antibody of  claim 18  comprising a variable heavy chain domain (VH) having at least 95% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 17 and a variable light chain domain (VL) having at least 95% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 18. 
     
     
         20 . The antibody of  claim 18  comprising a variable heavy chain domain (VH) with the amino acid sequence of SEQ ID NO: 17 and a variable light chain domain (VL) with the amino acid sequence of SEQ ID NO: 18. 
     
     
         21 . The antibody of claim  1 , wherein the antibody is a Fab fragment that binds to TPBG. 
     
     
         22 . An isolated nucleic acid encoding the antibody of  claim 18 . 
     
     
         23 . A host cell comprising the nucleic acid of  claim 22 . 
     
     
         24 . A method of producing an antibody comprising culturing the host cell of  claim 23  so that the antibody is produced. 
     
     
         25 . An immunoconjugate comprising the antibody of  claim 18 , and a cytotoxic agent. 
     
     
         26 . The immunoconjugate of  claim 25 , wherein the cytotoxic agent is  Pseudomonas  exotoxin A or a variant thereof. 
     
     
         27 . The immunoconjugate of  claim 25 , wherein the antibody is a Fab fragment that binds to TPBG. 
     
     
         28 . A pharmaceutical formulation comprising the antibody of  claim 18 , and a pharmaceutically acceptable carrier. 
     
     
         29 . A pharmaceutical formulation comprising the immunoconjugate of  claim 25  and a pharmaceutically acceptable carrier. 
     
     
         30 . A method of treating cancer in a patient, comprising administering the antibody of  claim 18  to a patient in need thereof. 
     
     
         31 . The method of  claim 30 , wherein the cancer is non-small cell lung cancer. 
     
     
         32 . A method of treating cancer in a patient, comprising administering the immunoconjugate of  claim 25  to a patient in need thereof. 
     
     
         33 . The method of  claim 32 , wherein the cancer is non-small cell lung cancer.